Dec 17, 2018 • 7:00 am EST Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
Nov 8, 2018 • 7:00 am EST Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Nov 6, 2018 • 8:00 am EST Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
Nov 5, 2018 • 8:00 am EST Corbus Pharmaceuticals to Announce Third Quarter 2018 Operational and Financial Results on November 8, 2018
Oct 22, 2018 • 8:00 am EDT Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
Oct 18, 2018 • 4:05 pm EDT Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference
Oct 3, 2018 • 9:00 am EDT Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
Sep 26, 2018 • 8:00 am EDT Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
Sep 20, 2018 • 7:00 am EDT Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study
Sep 18, 2018 • 8:05 am EDT Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union